Phil Rivers Technology today announced that its breakthrough candidate drug PR00012 has received clinical trial approval from the National Medical Products Administration (NMPA) Center for Drug Evalua···...[Read more]
Recently, Phil Rivers Technology (Beijing) Ltd. announced that Dr. Jianfei Yang has officially joined Phil Rivers Technology as Chief Scientific Officer (CSO). In view of the unique insights generated···...[Read more]
In recent years, the topic of AI drug development has received extensive attention.The successful application cases and development prospects of AI technologies in other industries have triggered grea···...[Read more]
On September 16, 2022, the 1st China (Hefei) Scenario Innovation Conference sponsored by Hefei Municipal People's Government and Great Wall Strategic Consulting and organized by Hefei Development ···...[Read more]
On September 7, 2022, the award ceremony of " Rising Star" of biomedicine will be held in Zhangjiang AI Island(AIsland).. Liu Ping, deputy director of the shanghai municipal commission of ec···...[Read more]
CSDR and Relevant Units to Investigate "Computational Medicine"...[Read more]
On August 26, 2022, the special session "Production Quality Management in the Whole Life Cycle of Drugs and Packaging", organized by Huiyu Research Institute Of Pharmaceutical Packaging Tech···...[Read more]
From August 19 to 20, 2022, DIA China Digital Clinical Trial Innovation Forum (dTrial Forum) was held in Suzhou Taihu Internation Conference Center. Zhao Yu, co-founder of Phil Rivers Technology, was ···...[Read more]
On August 10-11, 2022, the "Second AI Drug R & D Conference and AI Intelligent Drug Assisted Healthy China Theme Summit" was successfully held in Shanghai, China. A total of four major v···...[Read more]
On August 7, 2022, the third issue of the new target and new technology of the BiG live broadcast room was a hot review of the "AI+new drug" of the current fire. Dr. Niu Gang, co CEO of Phil···...[Read more]
扫一扫关注公众号